02:59 PM EDT, 08/08/2025 (MT Newswires) -- Health Catalyst ( HCAT ) shares were down over 23% in recent Friday trading after the company reported late Thursday Q2 results, lowered its 2025 revenue guidance and provided a Q3 outlook that fell short of analyst estimates.

The company reported Q2 adjusted net income $0.04 per diluted share, down from $0.12 a year earlier. Analysts polled by FactSet expected earnings of $0.03.

Revenue for the quarter ended June 30 was $80.7 million, up from $75.9 million a year ago. Analysts polled by FactSet expected $80.6 million.

The company said it now expects a full-year revenue to be about $310 million, down from its previous projection of $335 million. Analysts polled by FactSet expect $328.3 million.

The data and analytics company also projected its Q3 revenue to be about $75 million. Analysts polled by FactSet expect $83.5 million.

Separately, the company said Chief Executive Officer Dan Burton will step down from his role, effective June 2026.

Burton will continue to serve on the company's board and will aid in a search for a new CEO, Health Catalyst ( HCAT ) said.

Price: 2.84, Change: -0.86, Percent Change: -23.17